A trial of MUC-16 & IL-12 for the treatment of recurrent ovarian cancer.
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2016
At a glance
- Drugs JCAR 020 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jan 2016 According to an Eureka Therapeutics media release, the company opened this phase I trial in 2015.
- 07 Jan 2016 Status changed from not yet recruiting to recruiting, according to an Eureka Therapeutics media release.
- 20 Nov 2015 New trial record